Advertisement

Coronary Heart Disease in HIV-Infected Patients: Epidemiology

  • M. Mary-Krause
  • D. Costagliola

Abstract

Cardiovascular disease continues to be the leading cause of death among the general population of industrialized countries. It is also the main reason for hospitalization. But what about HIV-infected subjects? With the advent of combination antiretroviral therapy (cART) for HIV infection, including protease inhibitors (PIs), in April 1996 in France, the morbidity of AIDS-defining illnesses has been reduced and HIV-infected patients are living longer [1, 2]. Thus, the spectrum of diseases related to HIV is shifting from opportunistic diseases towards long-term complications such as cancers, coinfection with other viruses such as hepatitis C virus, and the metabolic effects of cART. Some of these disorders are potential risk factors for cardiovascular diseases and so could lead to cardiovascular over-mortality and over-morbidity. Cardiovascular diseases currently account for 7% of deaths among HIV-infected subjects in France, for 14% of non-HIV-related deaths [3], and about 16% of deaths among subjects with a good immunovirologic response to cART [4].

Keywords

Human Immunodeficiency Virus Coronary Heart Disease Human Immunodeficiency Virus Infection Coronary Heart Disease Risk Factor Human Immunodeficiency Virus Protease Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Palella FJ Jr, Delaney KM, Moorman AC et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med 338:853–860CrossRefPubMedGoogle Scholar
  2. 2.
    The CASCADE Collaboration (2000) Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 355:1158–1159CrossRefGoogle Scholar
  3. 3.
    Lewden C, Salmon D, Morlat P et al (2004) Causes of death among HIV-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 34:121–130CrossRefPubMedGoogle Scholar
  4. 4.
    May T, Lewden C, Bonnet F et al (2004) Causes et caractéristiques des décès des patients infectés par le VIH-1, en succes immuno-virologique sous traitement antirétroviral. Presse Med 33:1487–1492CrossRefPubMedGoogle Scholar
  5. 5.
    Delfraissy JF (2006) Prise en charge thérapeutique des personnes infectées par le HIV. Mise á jour 2006. Recommandations du groupe d’experts sous la direction du Pr P Yéni. Flammarion Médecine-Sciences, ParisGoogle Scholar
  6. 6.
    Hammer SM, Saag MS, Schechter M et al (2006) Treatment for adult HIV infection: 2006 recommendations of the International AIDS SocietyUSA Panel. JAMA 296:827–843CrossRefPubMedGoogle Scholar
  7. 7.
    Grunfeld C, Pang M, Doerrler W et al (1992) Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74:1045–1052CrossRefPubMedGoogle Scholar
  8. 8.
    Feingold KR, Krauss RM, Pang M et al (1993) The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 76:559–565CrossRefGoogle Scholar
  9. 9.
    Carr A, Samaras K, Burton S et al (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitor. AIDS 12:F51–F58CrossRefPubMedGoogle Scholar
  10. 10.
    Carr A, Samaras K, Thorisdottir A et al (1999) Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353:2093–2099CrossRefPubMedGoogle Scholar
  11. 11.
    Safrin S, Grunfeld C (1999) Fat distribution and metabolic changes in patients with HIV infection. AIDS 13:2493–2505CrossRefPubMedGoogle Scholar
  12. 12.
    Hadigan C, Meigs JB, Corcoran C et al (2001) Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 32:130–139CrossRefPubMedGoogle Scholar
  13. 13.
    Tabib A, Greenland T, Mercier I et al (1992) Coronary lesions in young HIV-positive subjects at necropsy. Lancet 340:730CrossRefPubMedGoogle Scholar
  14. 14.
    Paton P, Tabib A, Loire R, Tete R (1993) Coronary artery lesions and human immunodeficiency virus infection. Res Virol 144:225–231CrossRefPubMedGoogle Scholar
  15. 15.
    Henry K, Melroe H, Huebsch J et al (1998) Severe premature coronary artery disease with protease inhibitors. Lancet 351:1328CrossRefPubMedGoogle Scholar
  16. 16.
    Behrens G, Schmidt H, Meyer D et al (1998) Vascular complications associated with use of HIV protease inhibitors. Lancet 351:1958CrossRefPubMedGoogle Scholar
  17. 17.
    Gallet B, Pulik M, Genet P et al (1998) Vascular complications associated with use of HIV protease inhibitors. Lancet 351:1958–1959CrossRefPubMedGoogle Scholar
  18. 18.
    Laurence J (1998) Vascular complications associated with use of HIV protease inhibitors. Lancet 351:1960CrossRefPubMedGoogle Scholar
  19. 19.
    Flynn TE, Bricker LA (1999) Myocardial infarction in HIV-infected men receiving protease inhibitors. (letter) Ann Intern Med 131:548PubMedGoogle Scholar
  20. 20.
    Friedl AC, Attenhofer Jost CH, Schalcher C et al (2000) Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy. AIDS 14:2790–2792CrossRefPubMedGoogle Scholar
  21. 21.
    Karmochkine M, Raguin G (1998) Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factors who was treated with indinavir. AIDS 12:2499PubMedGoogle Scholar
  22. 22.
    Eriksson U, Opravil M, Amann FW, Schaffner A (1998) Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients? AIDS 12:2079–2080CrossRefPubMedGoogle Scholar
  23. 23.
    Koppel K, Bratt G, Rajs J (1999) Sudden cardiac death in a patient on 2 years of highly active antiretroviral treatment: a case report. AIDS 13:1993–1994CrossRefPubMedGoogle Scholar
  24. 24.
    Vittecoq D, Escaut J, Monsuez JJ (1998) Vascular complications associated with use of HIV protease inhibitors. Lancet 351:1959CrossRefPubMedGoogle Scholar
  25. 25.
    Passalaris JD, Sepkowitz KA, Glesby MJ (2000) Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis 31:787–797CrossRefPubMedGoogle Scholar
  26. 26.
    Jütte A, Schwenk A, Franzen D et al (1999) Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment? (letter) AIDS 13:1796–1797CrossRefPubMedGoogle Scholar
  27. 27.
    Rickerts V, Brodt HR, Staszewski S, Stille W (2000) Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: The Frankfurt HIV-cohort study. Eur J Med Res 5:329–333PubMedGoogle Scholar
  28. 28.
    Holmberg SD, Moorman AC, Williamson JM et al (2002) Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360:1747–1748CrossRefPubMedGoogle Scholar
  29. 29.
    Friis-Møller N, Sabin CA, Weber R et al (2003) Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349:1993–2003CrossRefPubMedGoogle Scholar
  30. 30.
    Moore RD, Keruly JC, Lucas G (2003) Increasing incidence of cardiovascular disease in HIV-infected persons in care. 10th conference on retroviruses and opportunistic infections, Boston, USA, 10-14 February 2003. Abstract no. 132Google Scholar
  31. 31.
    Mary-Krause M, Cotte L, Simon A et al (2003) Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIVinfected men. AIDS 17:2479–2486CrossRefPubMedGoogle Scholar
  32. 32.
    DAD Study Group, Friis-Møller N, Reiss P, Sabin CA et al (2007) Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356:1723–1735CrossRefPubMedGoogle Scholar
  33. 33.
    David MH, Hornung R, Fichtenbaum CJ (2002) Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clin Infect Dis 34:98–102CrossRefPubMedGoogle Scholar
  34. 34.
    Klein D, Hurley LB, Quesenberry CP, Sidney S (2002) Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 30:471–477PubMedGoogle Scholar
  35. 35.
    Klein D, Hurley M (2003) Hospitalizations for coronary heart disease and myocardial infarction among men with HIV-1 infection: additional follow-up. 10th conference on retroviruses and opportunistic infections, Boston, USA, 10-14 February 2003, Abstract no. 747Google Scholar
  36. 36.
    Bozzette SA, Ake CF, Tam HK et al (2003) Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348:702–710CrossRefPubMedGoogle Scholar
  37. 37.
    Bozette SA, Ake CF, Tam HK et al (2008) Longterm survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 47:338–341CrossRefGoogle Scholar
  38. 38.
    D’Arminio Monforte A, Sabin CA, Phillips AN et al (2004) Cardioand cerebrovascular events in HIV-infected persons. AIDS 18:1811–1817CrossRefGoogle Scholar
  39. 39.
    Sabin CA, Worm SW, Weber R et al (2008) Recent use of Abacavir and didanosine, but not of Thymidine Analogues, is associated with risk of myocardial infarction. 15th Conference on Retroviruses and Opportunistic Infections, Boston, USA, February 3-6, 2008. Abstract n957c.Google Scholar
  40. 40.
    DAD Study Group, Sabin CA, Worm SW, Weber R et al (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371:1417–1426CrossRefPubMedGoogle Scholar
  41. 41.
    Anonymous (2000) Les registres français de cardiopathies ischémiques 1997-1998. Fédération Française de cardiologie, ParisGoogle Scholar
  42. 42.
    Depairon M, Chessex S, Sudre P et al (2001) Premature atherosclerosis in HIV-infected individuals: focus on protease inhibitor therapy. AIDS 15:329–334CrossRefPubMedGoogle Scholar
  43. 43.
    Savès M, Chêne G, Ducimetière P et al (2003) Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 37:292–298CrossRefPubMedGoogle Scholar
  44. 44.
    Currier JS, Taylor A, Boyd F et al (2003) Coronary heart disease in HIV-infected individuals. J Acquir Immune Deficit Syndr 35:506–512Google Scholar
  45. 45.
    Smith C, Levy I, Sabin C et al (2004) Cardiovascular disease risk factors and antiretroviral therapy in HIV-positive UK population. HIV Med 5:88–92CrossRefPubMedGoogle Scholar
  46. 46.
    Anonymous (1977) Manuel de la classification statistique internationale des maladies, traumatismes et causes de décès, Révision 1975. Organisation Mondiale de la Santé, GenevaGoogle Scholar
  47. 47.
    Klein D, Hurley L, Silverberg M et al (2007) Surveillance data for myocardial infarction hospitalizations among HIV+ and HIVNorthern California. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, USA, 25-28 February 2007, Abstract no. 807Google Scholar
  48. 48.
    El-Sadr WM, Lundgren JD, Neaton JD et al; Strategies for Management of Antiretroviral Therapy (SMART) Study Group (2006) CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355:2283–2296CrossRefPubMedGoogle Scholar
  49. 49.
    Barbaro G, Di Lorenzo G, Soldini M et al Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS (GISCA) (1999) Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Circulation 100:933–939PubMedGoogle Scholar
  50. 50.
    Matetzky S, Domingo M, Kar S et al (2003) Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med 163:457–460CrossRefPubMedGoogle Scholar
  51. 51.
    Hsue PY, Giri K, Erickson S et al (2004) Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation 109:316–319CrossRefPubMedGoogle Scholar
  52. 52.
    Law M, Friis-Møller N, Weber R et al (2003) Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med 4:1–10CrossRefPubMedGoogle Scholar
  53. 53.
    Dube MP, Stein JH, Aberg JA et al (2003) Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 37:613–627CrossRefPubMedGoogle Scholar
  54. 54.
    Department of Health and Human Services (2004) Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. AIDSinfo, Rockville, MD, USA. http://www. AIDSinfo.nih.gov/guidelines. Cited 23 March 2004Google Scholar
  55. 55.
    Fellay J, Boubaker K, Lederberger B et al (2001) Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV cohort Study. Lancet 358:1322–1327CrossRefPubMedGoogle Scholar
  56. 56.
    Friis-Møller N, Weber R, Reiss P et al (2003) Cardiovascular disease risk factors in HIV patientsassociation with antiretroviral therapy. Results from the DAD study. AIDS 17:1179–1193Google Scholar
  57. 57.
    Fontas E, van Leth F, Sabin CA et al (2004) Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 189:1056–1074CrossRefPubMedGoogle Scholar
  58. 58.
    Haubrich RH, Riddler S, DiRienzo G et al (2007) Metabolic Outcomes of ACTG 5142: A Prospective, Randomized, Phase III Trial of NRTI-, PI-, and NNRTI-sparing Regimens for Initial Treatment of HIV-1 Infection. 14th conference on retroviruses and opportunistic infections, Los Angeles, USA, February 25-28, 2007. Abstract no. 38Google Scholar
  59. 59.
    van der Valk M, Friis-Moller N, Sabin C et al (2006) Effects of different interventions to improve ART-associated dyslipidemia. 8th international congress on drug therapy in HIV infection, Glasgow, UK, November 12-16, 2006. Abstract no. PL12.2Google Scholar
  60. 60.
    Falusi OM, Aberg JA (2001) HIV and cardiovascular risk factors. AIDS Reader 11:263–268PubMedGoogle Scholar
  61. 61.
    Chiuve SE, McCullough ML, Sacks FM, Rimm EB (2006) Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications. Circulation 114:160–167CrossRefPubMedGoogle Scholar
  62. 62.
    Glass TR, Ungsedhapand C, Wolbers M et al (2006) Prevalence and risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV cohort study. HIV Med 7:404–410CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2009

Authors and Affiliations

  • M. Mary-Krause
    • 1
  • D. Costagliola
    • 1
  1. 1.INSERM U720, Epidémiologie Clinique et Traitement de l’Infection à VIHUniversité Pierre et Marie CurieParisFrance

Personalised recommendations